| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-062 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的补充公告 2025 年 6 月 25 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"公司"）于 2025 年 2 月 28 日在上 海证券交易所网站（www.sse.com.cn）、《上海证券报》披露了《华康股份关于 回购注销部分限制性股票减少注册资本暨通知债权人的公告》（2025-018）。 根据市场监督管理部门关于工商变更的相关要求，现将相关内容补充如下 （加粗部分为本次补充披露内容）：以上事项公司将注销 2,821,000 股股份，注 销事项办理完成后，公司股份总数将由 305,869,175 股变更为 303,048,175 股。公 司注册资本由原来的 305,869,175 元变更为 303,048,175 ...

截至本公告披露日，公司已收到了上述全资子公司全部分红款 50,000,000.00 元人民币。 焦作华康为公司纳入合并报表范围内的全资子公司，本次所得分红将增加母 公司 2025 年度净利润，但不增加公司 2025 年度合并报表净利润，因此不会影响 2025 年度公司整体经营业绩。 特此公告。 浙江华康药业股份有限公司 浙江华康药业股份有限公司 关于收到全资子公司分红款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"公司"）全资子公司焦作市华康糖 醇科技有限公司（以下简称"焦作华康"）于近日向公司进行现金分红，具体情 况如下： 根据天健会计师事务所（特殊普通合伙）出具的天健审[2025]997 号审计报告， 截至 2024 年 12 月 31 日，焦作华康可供分配利润为 59,199,465.30 元人民币，经 股东决定，焦作华康以现金方式向公司分配利润 50,000,000.00 元人民币，剩余未 分配利润结转以后年度分配。 | 证券代码：605077 | 证券简称：华康股份 ...

华康股份(605077.SH)公告称，全资子公司焦作市华康糖醇科技有限公司向公司进行现金 分红，分红金 额为5000万元。该分红将增加母公司2025年度 净利润，但不增加公司2025年度合并报表净利润。 ...

Core Viewpoint - The article discusses the intensifying global competition for carbon neutrality and how the bio-based industry can address three major contradictions: reliance on upstream raw materials, certification barriers in the midstream, and limitations in downstream applications [1] Group 1: Event Overview - A closed-door meeting focused on industry breakthroughs was held from May 25-27 during the 2025 Bio-based Conference and Exhibition in Shanghai [4] - The "2025 Bio-based Industry Strategic Seminar" was co-hosted by DT New Materials and the Zhoushan Investment Promotion Center [4] - 25 representatives from industry associations, well-known brands, material companies, and research institutions gathered to discuss three core topics: market reshaping, policy collaboration, and technological breakthroughs [6] Group 2: Key Insights from the Opening Report - The opening report emphasized that bio-based materials are a core pathway for the chemical industry to achieve sustainable development [8] - It highlighted that China's "dual carbon" policy is accelerating implementation, with industry associations promoting collaborative development through policy recommendations, standard setting, and technological rewards [8] Group 3: Brand User Demands - Certification and traceability have become essential prerequisites for collaboration, with international brands requiring non-food bio-based raw material certification [10] - Brands are generally willing to accept a price increase of up to 10%, but significant cost increases could hinder market promotion [11] - Performance must be contextualized, with specific demands for lightweight and decorative bio-based materials in automotive parts and integrated packaging solutions in cosmetics [11] Group 4: Strategies for Bio-based Material Companies - The industrialization of FDCA (2,5-furandicarboxylic acid) faces challenges, with current prices being 40 times that of PTA, making large-scale production crucial for cost reduction [14] - Companies need to identify unique value scenarios beyond merely replacing petroleum-based materials [14] - There is a call for policy collaboration to align with the EU's Packaging and Packaging Waste Regulation (PPWR) and to develop a bio-based materials standard system in China [14] Group 5: AI Empowerment in Bio-manufacturing - Companies shared practices of using AI to reduce R&D costs by 30% through protein modification, enhancing enzyme efficiency, and shortening development cycles [16] - Addressing purity issues is critical for high-end applications, with a need for collaboration across the entire supply chain [16] Group 6: Zhoushan's Strategic Positioning - Zhoushan aims to become a new hub for the bio-based industry by attracting projects related to PLA, PHA, FDCA-PEF, and other materials, providing comprehensive support [17] - The region has already gathered benchmark companies, indicating an initial scale of the industry chain ecosystem [17] Group 7: Consensus on Industry Collaboration - The meeting reached three core conclusions: 1. Non-food raw materials are essential for large-scale commercialization, requiring dual drivers of policy and technological innovation [20] 2. Accelerating the establishment of carbon footprint standards aligned with international norms is necessary to break down green trade barriers [20] 3. Collaboration between brands and material suppliers is needed to shift from performance substitution to value creation [20] - The meeting emphasized that bio-based materials represent a shift in competition rather than a shortcut, necessitating collective efforts across the entire industry chain to overcome the "valley of death" from laboratory to large-scale production [20]

Core Viewpoint - The article discusses the intensifying global competition for carbon neutrality and how the bio-based industry can address three major contradictions: reliance on upstream raw materials, certification barriers in the midstream, and limitations in downstream applications [1]. Group 1: Event Overview - The 2025 Bio-based Industry Strategic Seminar was held from May 25-27 in Shanghai, focusing on industry breakthroughs [3]. - The seminar gathered 25 representatives from industry associations, well-known brands, material companies, and research institutions to discuss three core topics: market reshaping, policy collaboration, and technological breakthroughs [6]. Group 2: Key Insights from the Seminar - **Need for Certification and Traceability**: International brand representatives emphasized that non-food bio-based raw material certification (C14 testing + supply chain traceability) has become a prerequisite for collaboration [10]. - **Price Tolerance**: Brands are generally willing to accept a price increase of up to 10%, but a doubling of costs would hinder promotion [11]. - **Performance and Application**: Companies highlighted the need for bio-based materials to meet specific performance requirements, such as lightweight and decorative features for automotive parts, and integrated packaging solutions for cosmetics [12][14]. Group 3: Strategies for Bio-based Material Companies - **Cost and Purity Challenges**: The bio-based furan industry is focusing on overcoming the cost and purity challenges of FDCA, which is currently priced at 40 times that of PTA [14]. - **Identifying Unique Value Propositions**: Companies agreed that bio-based materials should leverage unique performance advantages rather than merely replacing petroleum-based materials [15]. - **Policy Collaboration**: There is a call for China to establish a bio-based material standard system in conjunction with the EU's packaging regulations to facilitate non-food raw material development [16]. Group 4: AI Empowerment in Bio-manufacturing - Companies shared practices of using AI to reduce R&D costs by 30% through protein modification, enhancing enzyme efficiency, and improving accuracy and speed in research [16]. Group 5: Regional Development Initiatives - Zhoushan is positioning itself as a new hub for the bio-based industry by attracting projects related to PLA, PHA, FDCA-PEF, and providing comprehensive support including raw material supply and industrial land [17]. Group 6: Consensus and Conclusions - The seminar reached three core conclusions: 1. Upstream raw materials must shift to non-food sources for large-scale commercialization, driven by policy and technological innovation [20]. 2. Accelerating the establishment of carbon footprint standards aligned with international norms is essential to break down green trade barriers [20]. 3. Collaboration between brands and material suppliers is necessary to redefine applications from "performance substitution" to "value creation" [20].

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting the company to clarify issues related to its construction projects and investment performance, particularly concerning the erythritol production project which has underperformed financially due to market conditions [1][2]. Summary by Sections Construction Projects and Investment - In 2024, the company invested 1.43 billion yuan in fixed assets, intangible assets, and other long-term assets, marking a 106.99% increase year-on-year. The fixed assets reached 2.25 billion yuan, up 45.13%, while construction in progress surged by 357.58% to 1.33 billion yuan, primarily due to the Zhoushan Huakang project [1]. - The erythritol production project generated revenue of 72.44 million yuan in 2024 but incurred a gross loss of 1.72 million yuan, continuing to fall short of initial projections since its trial operation began in May 2022 [1][2]. Erythritol Project Details - The total investment for the erythritol project is estimated at 350.41 million yuan, with cumulative investment reaching 362.68 million yuan by the end of 2024. The project aims to produce 30,000 tons of high-purity erythritol annually [5][6]. - In 2024, the company produced 6,834.50 tons of erythritol, achieving a sales rate of 97.96%. The market price for erythritol was approximately 13,000 yuan per ton by December 2024 [6][11]. Market Conditions and Competition - The erythritol market has faced significant challenges, including declining prices and increased competition, leading to a supply-demand imbalance. The price of erythritol has been under pressure since 2023, with some manufacturers exiting the market [7][11]. - The company noted that the market for erythritol was initially promising, but the influx of new competitors and expanded capacities led to a significant drop in prices, affecting profitability [7][11]. Inventory and Trade Business - By the end of 2024, the company's inventory reached 697 million yuan, a 147.26% increase year-on-year, primarily due to increased raw material reserves for the Zhoushan project. The raw materials accounted for 448 million yuan, up 385.15% [15][16]. - The cash flow from trade business payments was 1.15 billion yuan, reflecting a 198.58% increase, driven by the anticipated demand for corn from the Zhoushan project [15][16].

股票简称：华康股份 股票代码：605077 债券简称：华康转债 债券代码：111018 东方证券股份有限公司 关于浙江华康药业股份有限公司向不特定对象 发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 东方证券股份有限公司 （上海市黄浦区中山南路 318 号 24 层） 二零二五年五月 1 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《浙 江华康药业股份有限公司与东方证券股份有限公司关于向不特定对象发行可转 换公司债券至受托管理协议》（以下简称"《受托管理协议》"）、《浙江华康药业 股份有限公司向不特定对象发行可转换公司债券证券募集说明书》（以下简称 "《募集说明书》"）、《浙江华康药业股份有限公司 2024 年年度报告》等相关公 开信息披露文件、第三方中介机构出具的专业意见等，由本期可转换公司债券受 托管理人东方证券股份有限公司（以下简称"东方证券"）编制。东方证券对本报 告中所包含的从上述文件中引述内容和信息未进行独立验证，也不就该等引述内 容和信息的真实性、准确性和完整性做出任何保证或承担任何责任。本报告不构 成对投资者进行或不进行某项行为的推荐意 ...

东方证券股份有限公司 关于浙江华康药业股份有限公司 2024 年年度报告的信息披露监管问询函回复的核查意见 上海证券交易所： 根据贵所出具的《关于浙江华康药业股份有限公司 2024 年年度报告的信息 披露监管问询函》（上证公函【2025】0459 号）（以下简称"问询函"）的要求， 东方证券股份有限公司（以下简称"东方证券"、"保荐机构"）作为浙江华康药 业股份有限公司（以下简称"华康股份"或"公司"）首次公开发行股票并上市 的持续督导机构及向不特定对象发行可转换公司债券的保荐机构，对贵所问询函 提及的事项进行了核查、说明，并出具核查意见如下： 1、关于在建工程和募投项目。根据年报及相关公告，2024 年公司购建固定 资产、无形资产和其他长期资产支付的现金 14.30 亿元，同比增长 106.99%；2024 年末公司固定资产 22.54 亿元，同比增长 45.13%，在建工程 13.30 亿元，同比增 长 357.58%，主要系本期子公司舟山华康"100 万吨玉米精深加工健康食品配料 项目"（以下简称"舟山华康项目"）建设及部分转固所致。2024 年度公司募投 项目之一"年产 3 万吨高纯度结晶赤藓糖醇建设 ...

目 录 | 关于在建工程和募投项目………………………………………第 一、 | 1—3 | 页 | | --- | --- | --- | | 二、关于存货和贸易业务……………………………………………第 | 3—8 | 页 | | 三、关于往来款项………………………………………………… 第 | 8—13 | 页 | | 四、关于收购标的业绩和商誉……………………………………第 | 13—20 | 页 | | 五、关于主营业务…………………………………………………第 | 20—26 | 页 | 根据年报及相关公告，2024 年公司购建固定资产、无形资产和其他长期资 产支付的现金 14.30 亿元，同比增长 106.99%；2024 年末公司固定资产 22.54 亿元，同比增长 45.13%，在建工程 13.30 亿元，同比增长 357.58%，主要系本 期子公司舟山华康"100 万吨玉米精深加工健康食品配料项目"（以下简称"舟 山华康项目"）建设及部分转固所致。2024 年度公司募投项目之一"年产 3 万吨 高纯度结晶赤藓糖醇建设项目"实现收入 7243.55 万元、营业毛利润-172.15 万 元，自 2022 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于上海证券交易所对公司 2024 年年度报告的信息披露 监管问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司于 2025 年 4 月 28 日收到上海证券交易所下发 的《关于浙江华康药业股份有限公司 2024 年年报的信息披露监管问询函》（上 证公函【2025】0459 号）（以下简称"《监管问询函》"），根据上海证券交易所 的要求，经公司认真研究、核实与分析，现就《监管问询函》有关问题回复如 下： 一、关于在建工程和募投项目 根据年报及相关公告，2024 年公司购建固定资产、无形资产和其他长期资 产支付的现金 14.30 亿元，同比增长 106.99%；2024 年末公司固定资产 22.54 亿元，同比增长 45.13%，在建工程 13.30 亿元，同比增长 357 ...